Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oxybutynin transdermal gel - Antares

Drug Profile

Oxybutynin transdermal gel - Antares

Alternative Names: Anturol; AP-1034; Gelnique 3% Gel; Oxybutynin ATD™ gel

Latest Information Update: 15 Jul 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Antares Pharma
  • Developer Allergan; Antares Pharma
  • Class Alkynes; Antispasmodics; Carbocyclic acids; Cyclohexanes; Diethylamines; Esters; Mandelic acids; Small molecules
  • Mechanism of Action Cholinergic receptor antagonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Overactive bladder

Most Recent Events

  • 25 Jan 2013 Watson Pharmaceuticals is now called Actavis, Inc.
  • 26 Apr 2012 Launched for Overactive bladder in USA (Transdermal)
  • 17 Jan 2012 Oxybutynin transdermal gel licensed to Daewoong Pharmaceuticals in South Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top